🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

382 results for “Ology” Clear

  1. Toripalimab

    Coherus Oncology

    Localized Colon Carcinoma

    phase 2 small molecule active

    1 trial

  2. Toripalimab + Chemotherapy

    Coherus Oncology

    Head and Neck Cancer

    phase 2 small molecule active

    1 trial

  3. Toripalimab-tpzi

    Coherus Oncology

    Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  4. Trastuzumab

    PUMA BIOTECHNOLOGY, INC.

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  5. Tyenne 162 mg solution for injection in pre-filled pen

    Cardiff Oncology

    Psoriatic Arthritis, Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  6. Tyenne 162 mg solution for injection in pre-filled pen

    Cardiff Oncology

    Psoriatic Arthritis, Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  7. Ultravist 370 mg/ml soluzione iniettabile, OMNIPAQUE 350 mg I/ml soluzione iniettabile, VISIPAQUE 320 mg I/ml soluzione iniettabile

    Fondazione Telethon ETS

    breast pathology

    phase 2 small molecule active

    1 trial

  8. VELCADE 3.5 mg powder for solution for injection, DARZALEX 1800 mg solution for injection, DOXORUBICIN HYDROCHLORIDE, DEXAMETHASONE SODIUM PHOSPHATE, DOXORUBICIN HYDROCHLORIDE, CYCLOPHOSPHAMIDE

    Wuhan Createrna Science and Technology Co., Ltd

    Primary plasma cell leukemia

    phase 2 small molecule active

    1 trial

  9. VIR-2218

    Vir Biotechnology

    Hepatitis D, Chronic

    phase 2 small molecule active

    1 trial

  10. VIR-2218

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  11. VIR-2218

    Vir Biotechnology

    Chronic Hepatitis B

    phase 2 small molecule completed

    1 trial

  12. VIR-2482 (450 mg)

    Vir Biotechnology

    Influenza A

    phase 2 mab terminated

    1 trial

  13. VIR-3434

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  14. VIR-3434, VIR-2218

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 2 small molecule active

    1 trial

  15. VIR-5818

    Vir Biotechnology

    Locally Advanced or Metastatic HER2-Expressing Cancers

    phase 2 small molecule active

    1 trial

  16. VT30

    BridgeBio Oncology Therapeutics

    Venous Malformation

    phase 2 small molecule terminated

    1 trial

  17. Vancomycin

    Cardiff Oncology

    Late Onset Neonatal Sepsis

    phase 2 small molecule terminated

    1 trial

  18. Venetoclax, Venetoclax, Acalabrutinib, Venetoclax

    Wuhan Createrna Science and Technology Co., Ltd

    Patients with relapsed CLL, Chronic lymphocytic leukemia

    phase 2 small molecule active

    1 trial

  19. Vir-3434, Vir-2218, Pegasys 180 micrograms solution for injection in pre-filled syringe

    Vir Biotechnology

    Chronic Hepatitis B Virus Infection

    phase 2 small molecule active

    1 trial

  20. Xeloda 150 mg film-coated tablets, Xeloda 500 mg film-coated tablets, Paclitaxel 6 mg/mL concentrate for solution for infusion, Herceptin 150 mg powder for concentrate for solution for infusion, GEMZAR 200 mg, poudre pour solution pour perfusion, HALAVEN 0.44 mg/ml solution for injection, Vinorelbine 10 mg/ml concentrate for solution for infusion, GEMZAR 1000 mg, poudre pour solution pour perfusion, evorpacept, HALAVEN 0.44 mg/ml solution for injection

    ALX ONCOLOGY HOLDINGS INC

    Breast Cancer

    phase 2 small molecule active

    1 trial

  21. Xospata 40 mg film-coated tablets

    Wuhan Createrna Science and Technology Co., Ltd

    Acute myeloid leukaemia, Acute myeloid leukaemia

    phase 2 small molecule active

    1 trial

  22. Zanidatamab

    ALX ONCOLOGY HOLDINGS INC

    HER2-expressing Cancers

    phase 2 small molecule completed

    1 trial

  23. Zanubrutinib

    Wuhan Createrna Science and Technology Co., Ltd

    Cold agglutinin disease

    phase 2 small molecule active

    1 trial

  24. Ziftomenib

    Kura Oncology

    Advanced Malignant Neoplasm

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources